摘要
炭疽疫苗是预防炭疽流行和炭疽生物恐怖的重要手段。已有动物实验表明 ,炭疽活疫苗的保护力优于以保护性抗原为主要成份的无细胞疫苗 ,但两类现行疫苗都有待重新评价和改进。炭疽疫苗的效力必须用适当的实验室方法进行检测与分析才能了解其性质和细节。试验中力图探寻炭疽活疫苗家兔免疫力与血清抗芽胞抗体水平的关系。用“皮上划痕人用炭疽活疫苗”免疫家兔 ,以特定制备的炭疽芽胞抗原用ELISA法检测血清抗炭疽芽胞IgG抗体水平 ,并用强毒炭疽杆菌攻击进行效力试验。免疫家兔血清几何平均抗芽胞IgG滴度在免疫后一个月内持续升高 ,14d达到 2 0 6 ,2 8d时达到 776 ,这时其抵抗 2 0MLD毒菌攻击的保护率为 80 % ,符合中国生物制品规程要求的保护力。一个月后抗体水平开始下降 ,4 2d时滴度降至 2 2 3。实验所揭示的炭疽减毒活疫苗诱导的家兔抗芽胞IgG抗体与抗炭疽保护力之间的关系 ,既为评价现行疫苗提供了资料 。
Anthrax vaccine is essential to protect against the endemic and the bioterror of anthrax. In experimental animals,attenuated anthrax vaccines,live are more protective than acellular vaccines absorbed. But both kinds of current vaccines need to be re estimated and improved. The characters and details of the vaccines' efficacy should be detected and analysed with suitable experiments. Here,the aim is to search the correlation between the immunol protection and the anti spore antibody titer in potency test for live anthrax vaccine.Immunizing rabbits with live anthrax vaccine,detecting serological anti-spore IgG with special prepared anthrax spore antigen by ELISA,and perfoming potency test by challenging rabbits with virulent B.anthracis strain after immunization.The titers of animal sera anti spore IgG rised constantly in one month post immunization.The reciprocal geometric mean titer reached to 203 on day 14,to 776 on day 28. At the meantime the rabbits showed the protective rate of 80% against challenge with 20MLD virulent B.anthracis spores ,which was passed the national standard required by 'Chinese Requirements for Biological Products'.After one month the sera titers declined. It lowered to 223 on day 42. This experiment revealed the correlation between the immunol protection and the anti spore antibody titer in rabbit. This result provided not only the data to evaluate current vaccines,but the indicating index to develop new vaccines.
出处
《微生物学免疫学进展》
2003年第4期5-8,共4页
Progress In Microbiology and Immunology
关键词
炭疽杆菌
炭疽疫苗
炭疽芽胞抗原
血清IgG水平
疫苗效力试验
Bacillus anthracis
Anthrax vaccine
Anthrax spore antigen
Serological IgG level
Vaccine potency test
